Azure blue artpaper 24 x 121/1/2023 ![]() ![]() THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION, On payment services in the internal market, amending Directives 2002/65/EC,, 2009/110/EC and 2013/36/EU and Regulation (EU) No 1093/2010, and repealing Directive 2007/64/EC OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL Instructs its President to forward its position to the Council, the Commission and the national parliaments.ĪMENDMENTS BY THE EUROPEAN PARLIAMENT * Calls on the Commission to refer the matter to Parliament again if it intends to amend its proposal substantially or replace it with another text ģ. Adopts its position at first reading hereinafter set out Ģ. – having regard to the supplementary report of the Committee on Economic and Monetary Affairs (A8-0266/2015),ġ. – having regard to the Decision of the Conference of Presidents of 18 September 2014 on unfinished business from the seventh parliamentary term, – having regard to the amendments which it adopted at its sitting of 17 April 2014 , – having regard to the report of the Committee on Economic and Monetary Affairs and the opinion of the Committee on Legal Affairs ( A7-0169/2014), – having regard to Rule 59 and 61(2) of its Rules of Procedure, – having regard to the opinion of the European Economic and Social Committee of 10 December 2013 , – having regard to the opinion of the European Central Bank of 5 February 2014 , – having regard to Article 294(3) of the Treaty on the Functioning of the European Union, – having regard to Article 294(2) and Article 114 of the Treaty on the Functioning of the European Union, pursuant to which the Commission submitted the proposal to Parliament (C8‑0230/2013), – having regard to the Commission proposal to Parliament and the Council ( COM(2013)0547), (Ordinary legislative procedure: first reading) #AZURE BLUE ARTPAPER 24 X 12 TRIAL#These results support the need to further evaluate this compound in larger samples under double-blind conditions.Īttention Deficit Hyperactivity Disorder L-threonic acid magnesium salt clinical trial neuropharmacology.On the proposal for a directive of the European Parliament and of the Council on payment services in the internal market and amending Directives 2002/65/EC, 2013/36/EU and 2009/110/EC and repealing Directive 2007/64/EC Nearly half of participants met our definition of ADHD symptom clinical response. Conclusion: LTAMS supplementation was found to be effective and well tolerated. Changes in IQ and WASI-II performance were favorable and significant in the study population. Significant improvement was seen in the AISRS, CGI-I, and the shifting subscale of the BRIEF. ![]() Results: 47% of subjects met our criteria of response attaining a CGI-Improvement score ≤2 and AISRS total reduction ≥25%. The study was approved by the Institutional Review Board and posted on ClinicalTrails.Gov ( NCT02558790). Subjects received up to 12 weeks of open-label LTAMS administered as MMFS302 and MMFS202. Methods: Participants were 15 adults with ADHD of moderate severity. Preclinical work demonstrates that L-Threonic Acid Magnesium Salt (LTAMS) administration is associated with neurobiological and neurofunctional effects that could offer clinical benefits in ADHD treatment. Objective: Attention-deficit/hyperactivity disorder (ADHD) is estimated to affect up to 5% of adults worldwide. ![]()
0 Comments
Leave a Reply.AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |